Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than a third have stopped, new research shows.

A report by Blue Shield notes that more than half of people on weight loss medications such as Wegovy and Saxenda stop taking the drugs before they can reap the benefits

The number of young people in the US who are prescribed GLP-1 agonist drugs like Wegovy and Ozempic for weight loss and diabetes soared 594.4% in just three years, according to new research.